Skip to main content
. 2015 Oct 20;5:15336. doi: 10.1038/srep15336

Figure 2. Rebeccamycin-derivative VC1-8 has significant cell competition-promoting activity with least toxicity against normal cells.

Figure 2

(a) Cell survival ratio after treatment with Rebeccamycin (VC1) or its analogous compounds for 36 h. Data are mean ± SD from three independent experiments. Values are expressed as a ratio relative to DMSO treatment. (b) Structural formulae of Rebeccamycin (VC1) and VC1-8. The formulae of the other tested analogous compounds are shown in Supplementary Table 2a. (c) Effect of VC1-8 or VC1-10 on MDCK-pTR GFP-RasV12 cells mixed with MDCK cells (white bar) or cultured alone (gray bar). Data are mean ± SD from three independent experiments. Values are expressed as a ratio relative to DMSO treatment. *P < 0.05, ***P < 0.001. (d) Dose dependent effect of VC1-8 on MDCK-pTR GFP-RasV12 cells mixed with MDCK cells (white bar) or cultured alone (gray bar) after 16 h (top) or 36 h (bottom) treatment. Data are mean ± SD from three independent experiments. Values are expressed as a ratio relative to DMSO treatment. *P < 0.05, **P < 0.01, ***P < 0.001.